Rodman & Renshaw conference
Next monday, at Rodman & Renshaw conference in New York, when investors will see our 46% composite mortality compared to placebo (untreated) mortality of +60% with EAA>0.60 not randomized, I think that many of them will be interested to invest in Spectral.--------------------------------------------------------------With these numbers, trial results could be between 54-38% (16%) and 60-32% (28%) which are very plausible and very good for FDA approval.